Ipsen - Corrective statement amending the monthly disclosure of the total number of shares and voting rights as of June 30, 2026

Ipsen announced the completion of its acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK asset. This acquisition adds a first-in-class asset to Ipsen's Rare Disease pipeline. The announcement also includes a corrective statement regarding voting rights disclosure as of June 30, 2026.

07/22/2026, 12:00 PM • GlobeNewswire

Ipsen - Déclaration rectificative corrigeant la déclaration mensuelle du nombre total d'actions et de droits de vote au 30 juin 2026

Ipsen announced the completion of its acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK asset. This acquisition adds a first-in-class asset to Ipsen's Rare Disease pipeline. The company also published a corrective declaration regarding voting rights and share capital figures as of June 30, 2026.

07/22/2026, 12:00 PM • GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2026

Ipsen conducted share repurchases totaling 28,541 shares between July 6-10, 2026, at an average price of €166.05. The company announced that Dysport (botulinum toxin) achieved positive Phase III results in both episodic and chronic migraine trials, becoming the first botulinum toxin to meet primary endpoints in both indications.

07/15/2026, 12:00 PM • GlobeNewswire

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine xx - 2025

Ipsen conducted share buybacks between July 6-10, 2026, purchasing 28,541 shares at an average price of €166.05. The company announced that Dysport (botulinum toxin) achieved positive Phase III results in both episodic and chronic migraine trials, becoming the first botulinum toxin to meet primary endpoints in both indications.

07/15/2026, 12:00 PM • GlobeNewswire

GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma

GENFIT announced positive Phase 1b results for GNS561, an investigational drug targeting autophagy, in combination with a MEK inhibitor for treating advanced KRAS-mutated cholangiocarcinoma. The study of 19 patients showed a favorable safety profile with no dose-limiting toxicities and early signs of antitumor activity, with approximately half achieving stable disease. Phase 2 initiation is planned for the second half of 2026.

06/23/2026, 12:00 PM • GlobeNewswire

GENFIT : Données positives de Phase 1b obtenues avec GNS561 en combinaison, dans une population de patients atteints de cholangiocarcinome lourdement prétraités

GENFIT reported positive Phase 1b results for GNS561 combined with a MEK inhibitor in heavily pretreated cholangiocarcinoma patients with KRAS mutations. The drug demonstrated favorable safety and tolerability profiles with no dose-limiting toxicities, along with early signs of antitumor activity. Approximately half of the 19 patients achieved stable disease at Week 6, with one patient maintaining this status through Week 30. The company plans to extend Phase 1b with additional cohorts at higher doses and proceed to Phase 2 launch in H2 2026.

06/23/2026, 12:00 PM • GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2026

Ipsen conducted share buy-backs during the week of June 15-19, 2026, purchasing a total of 28,105 shares at a weighted average price of €156.21 per share on the Euronext Paris exchange. This represents part of the company's ongoing buy-back programme under MAR Article 5 regulations.

06/22/2026, 12:00 PM • GlobeNewswire

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 25 - 2026

IPSEN executed a share buy-back programme from June 15-19, 2026, purchasing a total of 28,105 shares at a weighted average price of €156.21 per share on the Euronext Paris exchange. The daily volumes ranged from 1,743 to 9,931 shares, with prices fluctuating between €155.47 and €157.21.

06/22/2026, 12:00 PM • GlobeNewswire

De nouvelles données "late-breaking" renforcent l’impact d’IQIRVO® sur l’ALP, la fatigue et le prurit dans la CBP.

Ipsen presented new clinical data on IQIRVO (elafibranor) at the EASL congress, demonstrating significant improvements in alkaline phosphatase (ALP) reduction, fatigue, and pruritus in primary biliary cholangitis (PBC) patients. Real-world data showed 59% of patients achieved ALP normalization at 6 months, while 67% of patients with moderate-to-severe fatigue showed clinically significant improvements compared to 31% on placebo at 52 weeks.

05/28/2026, 1:30 AM • GlobeNewswire

New late-breaking data reinforces IQIRVO®’s impact on ALP, fatigue and pruritus in PBC

Ipsen announced late-breaking results from the ELATIVE Phase III trial and real-world studies showing IQIRVO (elafibranor) demonstrated clinically meaningful improvements in fatigue, with 67% of patients achieving improvement versus 31% on placebo at Week 52. Real-world data showed 59% of patients achieved ALP normalization at 6 months, and the Phase IV ELFINITY study confirmed rapid ALP reductions and favorable tolerability in routine clinical practice.

05/28/2026, 1:30 AM • GlobeNewswire

Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity

Ipsen announced results from the DIRECTION trial, the first prospective head-to-head Phase IV study comparing Dysport (abobotulinumtoxinA) to Botox (onabotulinumtoxinA) in adults with upper limb spasticity. The trial met its primary and secondary endpoints, showing Dysport had a non-inferior safety profile to Botox while achieving longer-lasting symptom control (14.2 vs 13.8 weeks). Results will be presented at the ISPRM congress in Vancouver on May 19, 2026.

05/19/2026, 3:00 PM • GlobeNewswire

Ipsen annonce des données « late-breaking » issues de la première étude comparative directe entre Dysport® et Botox® chez des adultes atteints de spasticité du membre supérieur

Ipsen announced results from the DIRECTION study, the first direct head-to-head comparison of Dysport (abobotulinumtoxinA) and Botox (onabotulinumtoxinA) in adults with upper limb spasticity. The study met its primary safety endpoint, showing Dysport's safety profile is non-inferior to Botox, and achieved its secondary efficacy endpoint, demonstrating Dysport provides longer-lasting symptom control (14.2 vs 13.8 weeks). Results will be presented at the ISPRM World Congress in Vancouver on May 19, 2026.

05/19/2026, 3:00 PM • GlobeNewswire

Ipsen présente les derniers résultats d'une étude de phase II sur la corabotase, première de sa classe, concernant les rides glabellaires, montrant une durée d'effet prolongée et un niveau de satisfaction constamment élevé chez les patients

Ipsen announced Phase II trial results for corabotase (IPN10200), a first-in-class recombinant neuroinhibitor (RNITM), showing rapid onset (0.84 days) and sustained efficacy for glabellar wrinkles. At week 24, 60.8% of patients treated with corabotase (50 ng) achieved clinically significant sustained effect compared to 0.2% placebo and 36.7% Dysport, with 82.8% patient satisfaction. The 50 ng dose has been selected for Phase III LAURITE trials, with additional data expected for forehead and crow's feet indications.

05/16/2026, 8:00 AM • GlobeNewswire

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Ipsen announced Phase II trial results for corabotase, a first-in-class recombinant neuroinhibitor (RNITM), for treating moderate-to-severe glabellar lines. The drug demonstrated rapid onset (0.84 days), superior efficacy compared to placebo and Dysport at Week 24 (60.8% sustained clinical effect), and high patient satisfaction (82.8%). The 50ng dose was selected for Phase III LAURITE trials, with additional proof-of-concept data expected for forehead and lateral canthal lines.

05/16/2026, 8:00 AM • GlobeNewswire

DYSPORT Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan

A comprehensive market analysis report on Dysport (Ipsen's botulinum toxin type A) projects strong growth through 2034, driven by expanding neuromodulator and aesthetic injectable markets expected to reach $11.3B by 2028. Dysport holds 12% market share against Botox's 72%, leveraging competitive pricing and expanding therapeutic applications in neurological conditions. The report covers seven major markets including the US, EU4, UK, and Japan.

05/15/2026, 4:24 AM • GlobeNewswire